Company Encyclopedia
View More
name
Akero Therapeutics
AKRO.US
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc.
1.946 T
AKRO.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Akero Therapeutics Stockholders Approve Acquisition By Novo Nordisk

    Akero Therapeutics Inc :AKERO THERAPEUTICS INC - STOCKHOLDERS APPROVE ACQUISITION BY NOVO NORDISK - SEC FILING

    Reuters·
    US
    NVO
    +0.88%
    US
    AKRO
    -0.11%
    Reuters·
    US
    NVO
    +0.88%
    US
    AKRO
    -0.11%

    Akero Therapeutics Inc. Held Special Shareholder Meeting

    Akero Therapeutics Inc. held a special shareholder meeting on December 2, 2025, where stockholders approved its acquisition by Novo Nordisk A/S, including the merger and contingent value rights agreements. All proposals received necessary approval.

    Reuters·
    US
    NVO
    +0.88%
    US
    AKRO
    -0.11%
    Reuters·
    US
    NVO
    +0.88%
    US
    AKRO
    -0.11%

    Loomis Sayles & Co. L P Acquires 51,850 Shares of Akero Therapeutics, Inc. $AKRO

    Loomis Sayles & Co. L P increased its holdings in Akero Therapeutics, Inc. by 10.6% in the 2nd quarter, acquiring an additional 51,850 shares. The firm now owns 540,788 shares worth $28.86 million. Several other institutional investors also modified their holdings. Akero Therapeutics' stock performance and recent analyst ratings were discussed, with a consensus rating of 'Hold' and an average target price of $73.38. Insider transactions were also noted, including sales by Timothy Rolph and CFO William Richard White.

    Market Beat·
    US
    AKRO
    -0.11%
    Market Beat·
    US
    AKRO
    -0.11%

    Officer Rolph Acquires 152,678 Of Akero Therapeutics Inc [AKRO]

    Officer Rolph Timothy of Akero Therapeutics Inc filed a Form 4 with the SEC, disclosing the acquisition of 152,678 shares at $4.09 each, totaling $624,102. The transaction involved exercising options with varying expiration dates, resulting in direct holdings of 282,149 shares. The Washington Service offers insider trading analysis and data services.

    Reuters·
    US
    AKRO
    -0.11%
    Reuters·
    US
    AKRO
    -0.11%

    CEO Cheng Gifts 74,538 Of Akero Therapeutics Inc [AKRO]

    Cheng Andrew Chief Executive Officer of Akero Therapeutics Inc [AKRO] filed a Form 4 on November 21, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/20/25TransactionGiftShares74,538Price$0.00ValueN/AEnding Holdings: 436,837 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    AKRO
    -0.11%
    Reuters·
    US
    AKRO
    -0.11%
    © 2025 Longbridge｜Disclaimer